Lack of Pharmacokinetic Drug Interaction between Tenofovir Disoproxil Fumarate and Nelfinavir Mesylate
Open Access
- 1 October 2005
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (10) , 4386-4389
- https://doi.org/10.1128/aac.49.10.4386-4389.2005
Abstract
A study explored the pharmacokinetics of tenofovir (300 mg administered once daily) and nelfinavir (1,250 mg twice daily) when coadministered in 29 healthy volunteers. Tenofovir, nelfinavir, and M8 pharmacokinetics was unaltered when tenofovir and nelfinavir were coadministered, and tenofovir administration did not affect the M8/nelfinavir area under the concentration-versus-time curve over the dosing interval (AUCtau) ratio. No interaction between tenofovir and nelfinavir was observed.Keywords
This publication has 7 references indexed in Scilit:
- The Steady-State Pharmacokinetics of Nelfinavir in Combination with Tenofovir in HIV-Infected PatientsAntiviral Therapy, 2005
- Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjectsBritish Journal of Clinical Pharmacology, 2004
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 InfectionAnnals of Internal Medicine, 2003
- Tenofovir Diphosphate Is a Poor Substrate and a Weak Inhibitor of Rat DNA Polymerases α, δ, and ε*Antimicrobial Agents and Chemotherapy, 2002
- Therapeutic drug monitoring in HIV infection: current status and future directionsAIDS, 2002
- Transendothelial migration of leukocytes carrying infectious HIV-1: an indicator of adverse prognosisAIDS, 2002